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Human DNA methylomes of neurodegenerative diseases show
common epigenomic patterns
JV Sanchez-Mut1, H Heyn1, E Vidal1, S Moran1, S Sayols1, R Delgado-Morales1, MD Schultz2,3, B Ansoleaga4, P Garcia-Esparcia4,
M Pons-Espinal5,6, MM de Lagran5,6, J Dopazo7, A Rabano8, J Avila9,10, M Dierssen5,6, I Lott11, I Ferrer4, JR Ecker2,12 and M Esteller1,13,14
Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and
synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as
those affecting DNA methylation, might also exist. The studied samples were gray matter samples from the prefrontal cortex of
control and neurodegenerative disease-associated cases. We performed the DNA methylation analyses of Alzheimer’s disease,
dementia with Lewy bodies, Parkinson’s disease and Alzheimer-like neurodegenerative proﬁle associated with Down’s syndrome
samples. The DNA methylation landscapes obtained show that neurodegenerative diseases share similar aberrant CpG methylation
shifts targeting a deﬁned gene set. Our ﬁndings suggest that neurodegenerative disorders might have similar pathogenetic
mechanisms that subsequently evolve into different clinical entities. The identiﬁed aberrant DNA methylation changes can be used
as biomarkers of the disorders and as potential new targets for the development of new therapies.
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INTRODUCTION
Neurodegenerative diseases are complex disorders caused by the
convergence of genetic and environmental factors in aging. In
general, none of these factors has complete penetrance and only
the combination of some of them lead to the onset of the disease.
In this context, epigenetics, acting as a mediator between genome
and environment, provides a mechanistic explanation that might
offer unique opportunities to increase our understanding of such
disorders.1,2 As a consequence, it is not surprising that a number
of epigenetically deregulated genes are emerging, allowing us a
ﬁrst glimpse of the importance of epigenetics in neurodegenera-
tive diseases.3–10
The classiﬁcation of patients into different neurodegenerative
disease categories according to the preponderance of symptoms
has been important for gaining insight into their pathological
hallmarks but it is striking that often no clear distinctions can be
made between diseases. Instead, a continuous range of abnorm-
alities is typically observed that, unfortunately, complicates the
classiﬁcation.11 The overlap between these diseases could be partly
because similar processes are affected in all the disorders. For
example, considering the classic pathological hallmarks, we observe
that amyloid plaques, which are one of main characteristics of
Alzheimer’s disease (AD), are also more frequent in dementia with
Lewy bodies (DLB) and the early onset of Alzheimer-like neurode-
generative proﬁle associated with Down’s syndrome (DS); and that
the accumulation of normally soluble proteins into ﬁlamentous
insoluble aggregates, such as TAU-neurotangles, which are tradi-
tional hallmarks of AD and DS, are also found in Parkinson’s disease
(PD) and DLB. Similarly, characteristic hallmarks of PD and DLB, such
as α-synuclein inclusions, are also found in many cases of AD and
DS.12–17 There is multiple molecular crossover between these
pathways; for example, the α-synuclein protein interacts with TAU,
inducing its phosphorylation and aggregation while, simulta-
neously, TAU enhances α-synuclein aggregation.18
To determine whether these neurodegenerative disorders share
a common epigenomic defect we obtained the complete human
DNA methylomes of the prefrontal cortex of AD, DLB, PD and DS
patients at base resolution using whole-genome bisulﬁte sequen-
cing (WGBS).19–21 We have recently successfully used this method
to determine the DNA methylation patterns during the develop-
ment of the human and mouse brain.19 Combining these ﬁndings
with those from comprehensive DNA methylation microarrays,22,23
we have discovered a DNA methylation landscape that, at the
level of both CpG and non-CpG methylation, exhibits a similar
pattern of epigenomic disruption for all the neurodegenerative
diseases studied here.
MATERIALS AND METHODS
Human samples
Post-mortem tissues were obtained from the Institute of Neuropathology
Brain Bank (HUB-ICO-IDIBELL Biobank) following the practice and expertise
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of BrainNet Europe Bank (http://www.brainnet-europe.org/) ‘Network of
Excellence’ funded by the European Commission in the sixth Framework
Program ‘Life Science’ (LSHM-CT-2004-503039). All samples were obtained
in agreement with ethical standards and legislation deﬁned by the
European Union and following the approval of the local ethics committee.
DNA was extracted from the gray matter of the dorsolateral prefrontal
cortex (Brodmann area 9). Previously reported WGBS gray and white
matter data from the same control donor were used (female, 64 years old;
Lister et al.21). Gray matter from AD (female, 81 years old), DS with AD
(male, 41 years old), DLB (female, 77 years old) and PD (female, 77 years
old) was extracted for WGBS. Five gray matter samples for each group were
hybridized on 450K arrays, and 32 control (9 ± 1 h postmortem interval;
aged 66.8 ± 12.0 years), 32 AD (8 ± 1 h postmortem interval; aged
81.6 ± 14.7 years), 5 DS–AD (4 ± 1 h postmortem interval; aged 50.8 ± 9.1
years), 23 DLB (8 ± 1 h postmortem interval; aged 75.5 ± 13.6 years) and 15
PD (7 ± 1 h postmortem interval; aged 72.9 ± 13.1 years) samples were used
for pyrosequencing validation.
Pyrosequencing
The set of primers for PCR ampliﬁcation and sequencing was designed
using the software PyroMark assay design version 2.0.01.15 (Qiagen,
Valencia, CA, USA); ampliﬁcation primers hybridize with CpG-free sites to
ensure a methylation-independent reaction, and one primer (opposite the
sequencing primer) is biotinylated to convert the PCR product to single-
stranded DNA templates. We used 10 ng of bisulﬁte-treated DNA for each
PCR. We used the Vacuum Prep Tool (Qiagen) to prepare single-stranded
PCR products according to the manufacturer’s instructions. Pyrosequen-
cing reactions and methylation quantiﬁcation were performed in a
PyroMark Q24 System version 2.0.6 (Qiagen). Primers are available upon
request.
Whole-genome bisulﬁte sequencing data processing
We performed sequence alignment and methylation calling with Bismark
v.0.7.4 software (Cambridge, UK). We used hg19 as the reference genome
and retrieved genomic information from Biomart (Mansﬁeld, UK). SAM/
BAM and BED ﬁle-handling was done using SAMtools, bedtools and Tabix.
Statistical analysis and graphic representation was carried out with R
(http://www.R-project.org) and the multicore and ggplot2 libraries. We
deﬁned the promoter region as 2 kb ﬂanking the transcription start site,
which was considered to be the most upstream base of all the transcripts
of the gene. When depicting methylation proﬁles, we used the previously
described smoothing method.
CpG distance correlation
We assessed distance correlation of CpG in close proximity, gathering
information about methylation and relative distance up to 2000 bases
away from all CpG sites, and correlating pair-wise methylation at single
CpG sites for each relative distance.
Detection of DMRs
Differentially methylated regions (DMRs) were identiﬁed by seeking
regions with more than ﬁve consecutive CpG sites consistently located
outside the 95% conﬁdence interval of the smoothed methylation proﬁle.
Detection of histone marks
We obtained human histone marks for human adult brain inferior temporal
lobe available from the ENCODE project (GSE17312) and CCAT peak caller,
using the standard parameter for histone marks.
Microarray-based DNA methylation analysis with the Inﬁnium
450K array
The Inﬁnium DNA methylation microarray (Illumina, San Diego, CA, USA)
assay was performed as previously previously.22,23
RESULTS
WGBS of DNA from gray matter and neurodegenerative disorders
Initial data were generated from the gray matter of a control
sample (G145) (64-year-old female Caucasian), and samples of AD
(81-year-old female Caucasian), DLB (77-year-old female Cauca-
sian), PD (77-year-old female Caucasian) and neurodegeneration
associated with DS (49-year-old male Caucasian) (Table 1), using
DNA extracted from the dorsolateral prefrontal cortex Brodmann
area 9, because this is particularly involved in higher cognitive
skills, such as memory and cognition, and is affected in these
neurodegenerative disorders.24
For WGBS, we generated ~ 20 × 107 80–90-bp paired-end reads
corresponding to a global coverage of ~ 10 × sequencing depth.
We successfully mapped ~ 94% of the genome for the studied
samples. WGBS coverage and number of reads for each
sequenced gray matter case are summarized in Table 1. For all
subsequent analyses, to avoid possible gender-related differences,
the DNA methylation values derived from the X-chromosome
were not included, although other differences in autosomes
cannot be completely discarded. The full WGBS data set from the
studied gray matter samples is illustrated in Figure 1a, using
Circos.25 The total number of methylated CpG dinucleotides and
the methylcytosine, methyl CpG and non-methyl CpG levels of the
samples are shown in Figure 1b. The average methylation level of
all CpG sites was similar in the normal and disease-affected gray
matter sample, with values ranging from 77.7 to 80.6%. The
average methylation level of cytosines in non-CpG sites for all the
analyzed samples ranged from 4.3 to 7.3% (Figure 1b). These non-
CpG methylation values were similar to those previously reported
in brain tissues.19 We also observed a correlation in terms of the
methylation status of nearby CpGs, which decreases with distance,
as we had observed in other tissues,20 and showed similar proﬁles
in all samples (Figure 1c). In contrast, no correlation was observed
for non-CG methylation (Figure 1c), probably because non-CG
methylation is more scattered throughout the genome.19,26 Owing
to its proven functional signiﬁcance and abundance,27 we focused
subsequent analyses on CpG methylation modiﬁcation.
Identiﬁcation of DMRs
To characterize genomic sequences with a distinct CpG methyla-
tion status in the control gray matter and the neurodegenerative
Table 1. WGBS samples and general data summary
Sample description Deep sequencing data
Code Neurodegenerative disease Region Age Gender Individual group Coverage No. of reads
A09 Alzheimer’s disease BA9 gray matter 81 Female Caucasian 10.8 × 193 166 927
DLB2 Dementia with Lewy bodies BA9 gray matter 77 Female Caucasian 8.3 × 150 659 414
BK1027 Parkinson’s disease BA9 gray matter 77 Female Caucasian 12.1 × 231 693 584
31_08 Down syndrome with Alzheimer’s disease BA9 gray matter 49 Male Caucasian 11.0 × 199 508 612
G145 Control gray matter BA9 gray matter 64 Female Caucasian 10.6 × 190 679 672
W145 Control white matter BA9 white matter 64 Female Caucasian 10.7 × 191 543 442
Abbreviations: BA9, Brodmann area 9; WGBS, whole-genome bisulﬁte sequencing.
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diseases under study, we searched for DMRs in the WGBS data
using smoothing algorithms.28 We thereby identiﬁed a range of
25 023–29 817 DMRs between the normal gray matter and the
neurodegenerative disorders that might reﬂect disease-associated
and inter-individual differences. DMRs may be associated with
distinct percentages of cell types in neurodegenerative diseases
where there is a decrease in the number of neurons and an
increase in the glial component. To avoid this troublesome
possibility in our samples, we performed WGBS in the white
matter (W145) of the brain sample in which we had characterized
the gray matter component (64-year-old female Caucasian). We
identiﬁed 26 914 DMRs that distinguished the gray and white
matters (G145 vs W145; Figure 2a). We excluded these sequences
from our analyses and obtained a range of 21 501–26 140 DMRs in
the control gray matter and the neurodegenerative disorder
samples. These DMRs are illustrated in Figure 2b using Circos.25
The DMRs associated with the neurodegenerative diseases were
present particularly in functionally relevant genomic sequences
(odds ratio (OR) = 2.4; bootstrap Po0.001), such as promoters
(OR= 5.1; bootstrap Po0.001), transcription factor-binding sites
(OR= 8.4; bootstrap Po0.001) and enhancers (OR= 4.1; bootstrap
Po0.001; Figure 2c). This observation was particularly striking in
promoters located in CpG islands (OR= 10.1; bootstrap Po0.001),
sequences that are key critical regulators of gene expression in
relation to their methylation status (Figure 2).
In line with the direct regulatory function of DNA methylation in
promoter regions, we found 14–18% (775–930 genes) of
differentially methylated genes to be associated with a change
in gene expression using gene expression microarray technology
and matching RNA from the previously proﬁled DNA samples
(41.5-fold expression change; Supplementary Tables S1–S4). In
particular, we identiﬁed 160–363 hypermethylated gene promo-
ters as being related to transcriptional repression (20–42% of
differentially expressed genes) and 59–112 hypomethylated
promoters as being associated with gene activation (8–14% of
differentially expressed genes; Supplementary Tables S1–S4).
Most importantly, among these differentially methylated genes
with an impact on gene expression in AD (Supplementary
Table S1), we conﬁrmed two recently discovered epigenetic
targets of the disorder: ankyrin 1 (ANK1) and rhomboid 5 homolog
2 (RHBDF2).9,10 We also further found differential methylation of
ANK1 in DLB (Supplementary Table S3).
The functional role of the identiﬁed DMRs was also highlighted
by their association with another critical layer of epigenetic
control, the post-translational modiﬁcation of histones.29 Using
the histone mark map for human adult brain inferior temporal
lobe available from the ROADMAP project (GSE17312) and the
CCAT peak caller,30 we observed that 495% of the DMRs co-
localized with euchromatin markers such as H3K4me1, H3K4me3,
H3K36me3 and H3K27ac (OR = 5.7; bootstrap Po0.001), while
0%
20%
40%
60%
80%
100%
Grey AD PD DS
C
pG
 m
et
hy
la
tio
n 
le
ve
l (
%
)
0%
20%
40%
60%
80%
100%
Grey AD PD DSn
on
-C
G
 m
et
hy
la
tio
n 
le
ve
l (
%
)
0%
20%
40%
60%
80%
100%
Grey AD PD DS
C
 m
et
hy
la
tio
n 
le
ve
l (
%
)
15,000,000
15,500,000
16,000,000
16,500,000
17,000,000
17,500,000
18,000,000
Grey AD PD DS
M
et
hy
la
te
d 
C
pG
 S
ite
s
DLBDLB
DLBDLB
Figure 1. Whole-genome bisulﬁte sequencing of neurodegenerative diseases. (a) Circos representation of genome-wide DNA methylation
levels in the control gray matter (Gray) and the affected gray matter of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), Parkinson’s
disease (PD) and Down’s syndrome (DS) individuals. Average levels for all of the CGs in 567 5-Mbp-wide windows. Average methylation levels
in all of the regions are expressed as β-values (0–1) and are colored blue. (b) Total number of methylated CpG sites and the percentage CpG
methylation level in the DNA from the control gray matter and the neurodegenerative disorders. Percentage 5-methylcytosine and non-CpG
methylation levels are also shown. (c) Correlation of methylation status vs distance between dinucleotides (on log scale) in both CpG context
(left panel) and non-CpG context (right panel) for the control gray matter sample and the neurodegenerative disorders samples determined
by WGBS. We present non-CpG context aggregated (blue line) and broken by dinucleotide (CA, red; CC, brown; CT, pink). A more pronounced
declining curve indicates a lower correlation in terms of the methylation status of nearby CpGs.
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heterochromatin regions remained largely under-represented in
our DMR setting (H3K9me3; OR= 1.3; bootstrap Po0.001;
Figure 2d). Furthermore, there was a particular enrichment on
bivalent domains (H3K4me3+H3K27me3) in our DMRs (OR= 14.6;
bootstrap Po0.001; Figure 2d), which is an additional indication
of a putative functional role.
A common core of DNA methylation changes underlies
neurodegenerative diseases
To gain initial insight into the cellular pathways targeted by those
DMRs that overlapped gene promoter genes, we used the
gProﬁler analysis suite,31 which revealed a number of signiﬁcantly
overrepresented KEGG pathways that inﬂuence brain develop-
ment and function (Table 2). These included not only synapse
pathways, genes associated with the regulation of cytoskeleton,
neurotrophin and ErbB signaling but also developmental networks
such as those associated with the Wnt and Hippo pathways
(Table 2). The striking overlap of the epigenetically enriched,
disrupted pathways between AD, DLB, PD and DS prompted us to
examine whether a common core of genes did indeed have
altered DNA methylation patterns for all these neurodegenerative
disorders.
We adopted a dual approach to assess the commonality of
DMRs among the four neurodegenerative diseases. First, following
a very stringent criterion, we examined how many of the DMRs
occurred in overlapping promoter sequences for the characterized
disorders. This strategy yielded 709 DMRs that were present in all
these neurodegenerative diseases, including 257 differentially
methylated gene promoters (Figure 3a and Supplementary Table
S5). Second, in a relatively less stringent manner, we assessed how
many of the DMRs occurred in the same gene promoters even
though their sequences did not overlap. This approach yielded
1545 DMRs that were shared by AD, DLB, PD and neurodegenera-
tion associated with DS (Figure 3a and Supplementary Table S6).
To further validate the DNA methylation signature obtained for
the neurodegenerative diseases, we sought to extrapolate our
ﬁndings from the WGBS data and their corresponding DMR
analyses to a larger collection of samples of these disorders.
We used an established DNA methylation microarray that assays
the DNA methylation status of 450,000 CpG sites.22,23 Although we
have already shown that this microarray platform produces
Figure 2. Differentially methylated regions (DMRs) of neurodegenerative diseases. (a) Circos representation of average methylation levels for
all of the CGs in the DMRs between gray and white matters from the prefrontal cortex of the same person. Regions are equally spaced around
the ﬁgure and their original locations in the genome are indicated by gray lines. (b) Circos representation of average methylation levels for all
of the CGs in the DMRs between control gray matter and the affected gray matter of the studied neurodegenerative disorders. Regions are
equally spaced around the ﬁgure and their original locations in the genome are indicated by gray lines. (c) Molecular context of the identiﬁed
DMRs in neurodegenerative diseases. DMR distribution among different genomic sequences; DMR distribution among promoters with respect
to the presence or absence of a CpG island; DMR distribution among different post-translational histone modiﬁcation marks. *Po0.05;
**Po0.01; ***Po0.0001 in Fisher’s exact test.
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accurate DNA methylation data at a similar level than WGBS,20 we
nevertheless reassessed this ﬁnding. The methylation levels
obtained from all 450K CpG sites included in the microarray were
signiﬁcantly correlated with those values obtained with the WGBS
technology (Pearson correlation, r2 = 0.95, Po0.01; Figure 3c). As
the analysis of single samples impedes comprehensive statistical
analysis, we use the technically validated CpG sites located in the
709 and 1545 WGBS-derived DMRs common to all the diseases
under consideration for a profound validation in a larger sample
cohort using genome-scale analysis (450K). We found signiﬁcant
differences in the DNA methylation patterns between the control
gray matter and that derived from an additional set of 20 cases of
neurodegenerative disorders (multiscale bootstrap resampling,
n= 1000, Po0.0001), which enabled them to be distinguished by
hierarchical clustering (Figure 3d).
We further validated the differential DNA methylation status of
the identiﬁed CpG sites by developing a pyrosequencing assay for
20 top-ranked candidates of the WGBS-derived candidate genes
identiﬁed here (Supplementary Table S6) in an additional set of 32
control and 75 neurodegenerative disease-associated gray matter
samples (Figure 4 and Supplementary Table S7). In this setting, we
conﬁrmed the signiﬁcant differential methylation status of these
genes in AD, DLB, PD and DS relative to the control gray matter
(Figure 4), conﬁrming the aforementioned distinct CpG methyla-
tion patterns obtained from different samples and by different
techniques (WGBS and 450K DNA methylation microarray).
Overall, these results suggest that the most frequent human
neurodegenerative disorders share a number of epigenetic
alterations in target genes. The existence of an aberrant DNA
methylation landscape that is common to AD, DLB, PD and DS
could be used to devise new biomarkers of the diseases, and to
explain, in part, their physiopathology. This could provide a
scientiﬁc basis for the preclinical use of drugs targeting the
epigenome of neurodegenerative disorders.
DISCUSSION
In recent years the importance of DNA methylation in brain
functionality has gained increasing recognition.3–10 Several
studies, including ours, have focused on the determination of
the DNA methylation patterns of neurons and glia, whereas others
have concentrated on particular brain regions. Although these
have produced interesting ﬁndings, the analyses have some
limitations. For example, in examining speciﬁc regions, the distinct
cell-type makeup is often not taken into account, and the pure
comparison of the neurons and glial cells does not consider the
peculiarities of brain substructures. The two physiological
components, cell-type composition and local brain regions, cross
talk at the level of activity and it is known that neurons and glial
cells have speciﬁc spatial proﬁles associated with the classic
anatomical structures involved in particular functions.32,33 Another
limitation of many of the previous studies of brain epigenetics also
relates to the methods used, whereby only target candidate genes
or those sequences included in the available DNA methylation
arrays could be interrogated.3–8 To overcome these concerns, in
this study we obtained the complete and unbiased DNA
methylome by WGBS19,20 of an important and speciﬁc brain
region—the gray matter from the dorsolateral prefrontal cortex
Brodmann area 9 (ref. 24)—from normal status cases and from
four prevalent neurodegenerative disorders. We subtracted the
DNA methylome of the white matter from the same area to
identify the signiﬁcant DMRs that characterize the disorders.
Table 2. KEGG analysis of differentially methylated promoters
Term ID Description Diseases AD P-value DS P-value DLB P-value DS P-value
KEGG:04012 ErbB signaling pathway AD, DS, DLB and PD 0.0000387 0.0237 0.000331 0.00229
KEGG:04350 TGF-beta signaling pathway AD, DS, DLB and PD 0.0372 0.0237 0.0362 0.0326
KEGG:04810 Regulation of actin cytoskeleton AD, DS, DLB and PD 0.00191 0.0000792 0.0000258 0.0151
KEGG:04390 Hippo signaling pathway AD, DS, DLB and PD 0.00000599 3.17E-10 0.000187 0.0000209
KEGG:04310 Wnt signaling pathway AD, DS, DLB and PD 1.37E-07 0.000512 0.00011 0.0251
KEGG:04010 MAPK signaling pathway AD, DS, DLBD and PD 0.000156 0.0334 0.00000113 0.0000373
KEGG:04722 Neurotrophin signaling pathway AD, DS, DLB and PD 3.09E-07 0.0182 0.0000206 0.00000195
KEGG:04666 Fc gamma R-mediated phagocytosis AD, DS, DLB and PD 0.0000548 0.00623 0.000414 0.00738
KEGG:04115 p53 signaling pathway AD, DS, DLBD and PD 0.00052 0.0262 0.033 0.0000254
KEGG:04520 Adherens junction AD, DS, DLB and PD 0.000516 0.0299 0.00143 0.0197
KEGG:04340 Hedgehog signaling pathway AD, DS and DLB 0.032 0.0109 0.00309 —
KEGG:04725 Cholinergic synapse AD, DLB and PD 0.00341 — 0.0033 0.0106
KEGG:04110 Cell cycle AD, DS and PD 0.0000282 0.045 — 1.15E-07
KEGG:04724 Glutamatergic synapse AD and DLB 0.000733 — 0.0395 —
KEGG:04713 Circadian entrainment AD and PD 0.00286 — — 0.0376
KEGG:04728 Dopaminergic synapse AD and PD 0.0339 — — 0.03
KEGG:04360 Axon guidance DS and PD — 0.000119 — 0.0198
KEGG:04120 Ubiquitin-mediated proteolysis DS and PD — 0.0103 — 0.00156
KEGG:04151 PI3K–Akt signaling pathway DLB and PD — — 0.000028 0.00772
KEGG:04070 Phosphatidyl inositol signaling system DLB and PD — — 0.00198 0.0016
KEGG:04150 mTOR signaling pathway DLB and PD — — 0.0181 0.00127
KEGG:04710 Circadian rhythm AD 0.0411 — — —
KEGG:00532 Glycosaminoglycan biosynthesis—chondroitin
sulfate/dermatan sulfate
AD 0.00626 — — —
KEGG:04066 HIF-1 signaling pathway AD — — — —
KEGG:04530 Tight junction DS — 0.0158 — —
KEGG:00562 Inositol phosphate metabolism DLB — — 0.000316 —
KEGG:04510 Focal adhesion DLB — — 0.000525 —
KEGG:04910 Insulin signaling pathway PD — — — 0.0149
KEGG:04270 Vascular smooth muscle contraction PD — — — 0.0339
Abbreviations: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; DS, Down’s syndrome; HIF-1, hypoxia-inducible factor-1; MAPK, mitogen-activated
protein kinase; PD, Parkinson’s disease; TGF, transforming growth factor.
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Two recent global DNA methylation analyses of AD9,10 have
provided the ﬁrst complete DNA methylomes of the disorder.
These two independent epigenome-wide studies identiﬁed four
common aberrantly methylated genes (ANK1, RHBDF2, RPL13 and
CDH23). Our WGBS approach enabled us to validate these ﬁndings
for ANK1 and RHBDF2 in AD, and for ANK1 in DLB. In this regard,
and to the best of our knowledge, our study represents the ﬁrst
common analysis of the entire DNA methylomes at single-
nucleotide resolution of the most frequent neurodegenerative
diseases in western societies. In this context, additionally
obtaining the DNA methylomes of glial cells from the same area
was especially important because a speciﬁc loss of neurons occurs
in these neurodegenerative diseases that could have yielded false-
positive DMRs. Interestingly, we found an outstanding coincidence
of the DNA methylation alterations and their associated cellular
pathways present in the four neurodegenerative disorders studied
here. Thus, a common substrate of epigenetic defects underlies
these diseases, and this could help explain some of their shared
molecular, cellular and clinical features. In this regard, more than
50% of AD people show α-synuclein inclusions, whereas comorbid
AD pathologies, including β-amyloid plaques and neurotangles,
are commonly found in PD and DLB brains,15 and α-synuclein
inclusions are also frequently found in DS.12 It has also been
observed that familial forms of AD, harboring APP, PSEN1 or
PSEN2 mutations, present α-synuclein inclusions in more than
60% of cases, and that PD patients harboring the dominant
mutation A53T SNCA have a higher prevalence of dementia than
those with idiopathic forms.15 Furthermore, the incidence of
dementia in PD patients is up to six times that observed in normal
people.15 Therefore, our data are consistent with the aforemen-
tioned observations, and many others, that reinforce the idea that
these neurodegenerative diseases might represent a wide
spectrum of manifestations of pathologies with similar causative
mechanisms.
Although we cannot discard that our initially produced WGBS
data might represent a combination of disease-associated and
inter-individual differences, the subsequent thorough validation
steps performed in this study strongly supported the biological
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Figure 3. A common set of gene-associated DMRs for neurodegenerative diseases. (a) Venn diagram representing the shared DMRs for the
neurodegenerative disorders with respect to the DMRs present in overlapping promoter sequences. (b) Venn diagram representing the
shared DMRs for the neurodegenerative disorders that occurred in the same gene promoters but whose sequences did not overlap. (c)
Scatterplot comparison of CpG methylation level obtained by WGBS (x axis) and the Inﬁnium 450K array (y axis) technologies for each
analyzed sample. All differentially methylated CpG sites are shown that were identiﬁed by the WGBS approach and that were present on the
450K DNA methylation microarray. (d) Heatmap clustering of 450K DNA methylation microarray data representing the 747 (left) and 1545
(right) DMRs shared by all four neurodegenerative diseases. Red and green indicate high and low levels of DNA methylation, respectively.
Hierarchical clustering by Euclidian distance was carried out. AD, Alzheimer’s disease; CONT, control gray matter; DMR, differentially
methylated region; DLB; dementia with Lewy bodies; DS, Alzheimer-like neurodegenerative proﬁle associated with Down’s syndrome; PD,
Parkinson’s disease; WGBS, whole-genome bisulﬁte sequencing.
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meaning of our observations. In particular, following stringent
ﬁltering of the initial set of DMRs for cell-type composition, their
enrichment in functional genomic elements largely excludes
randomness of the identiﬁed loci. Importantly, the limitation of
small initial sample sizes was subsequently addressed combining
validation steps of larger sample cohorts at genome-scale and
loci-speciﬁc allowing a rigorous statistical analysis to conform the
signiﬁcance of the identiﬁed differential methylated loci. Strik-
ingly, considering the limited initial sample size and the small
absolute differences in DNA methylation between the diseases,
we could validate commonly differentially methylated loci
throughout the validation cohorts. This is of particular importance
as our approach could inﬂuence the design of future epigenome-
wide association studies in neurodegenerative diseases. In
contrary to genome-wide association study, epigenetic studies
might present signiﬁcant results already for smaller cohorts, due
to the less random character of DNA methylation changes that are
likely to be directly driven by the disease pathology. Considering
the ﬂexible character of epigenetic marks, inﬂuenced by aging
processes or environmental effects, it is important to widely
exclude confounding factor, such as age, gender or origin,
through a balanced sample design (as performed in the here-
presented study, Supplementary Table S7). It is of note that our
analysis of samples from both genders in a combined manner
could miss important variance within the gender groups (sex
chromosomes), which has to be addressed in future work using
larger gender-matched cohorts.
Further clues to the origin of these disorders can be found in
the pathways represented by the genes associated with the DMRs
characterized in our study. For example, we found that key genes
for brain development and cerebral cortex regionalization, such as
the Empty Spiracle Homeobox 1 and 2 (EMX1 and EMX2) genes,34
were aberrantly methylated in the neurodegenerative disorders.
These ﬁndings are linked to the recent observation that amyloid
peptide treatments can induce DNA methylation alterations in
genes involved in in vitro neuronal differentiation.35 Other
pathways associated with neurodegenerative diseases, such as
altered cyclic nucleotide signaling,36 illustrated by the protein
kinase cAMP-dependent regulatory type I alpha (PRKAR1A) and the
cGMP-dependent protein kinase type II (PRKG2) genes, were also
present in the identiﬁed DMRs. Interestingly, the characterized
CpG methylation sites might also pinpoint newly recognized
pathways in these disorders. This would include, for example, the
contribution of other epigenetic marks, such as histone modiﬁca-
tions related to the transducin-like enhancers of split 2 and split 4
proteins, which are both partners of the histone deacetylase 1
complex that has been linked to neurodegeneration.37 It would
also include the ﬁrst-in-class description of the disruption of DNA
methylation by a non-coding RNA (DQ599803) that is transcribed
from a piRNA genomic locus, a family of small non-coding RNAs
that are essential for neuronal plasticity and memory formation,38
and that are involved in TAU-mediated neurodegeneration.39
Further intense in vitro and in vivo work will be required in the
coming years to gather further evidence of the role of these
candidate genes in the origin and progression of these diseases.
In conclusion, we present the DNA methylation patterns of the
most common neurodegenerative disorders at the highest level of
resolution reported to date. The picture that emerges indicates
that AD, DLB, PD and DS share an aberrant DNA methylation
signature characterized by the presence of the disrupted CpG
methylation status of a set of common genes involved in many
cellular pathways. These ﬁndings suggest that the disorders might
have similar early pathogenetic mechanisms that subsequently
evolve into clinical entities with different molecular and cellular
features. The publicly deposited DNA methylation data obtained
here are important as reference epigenomes for these disorders,
and could be further explored using other bioinformatic
algorithms to derive additional relevant information about these
diseases. Although much effort will be required in the near future
to disentangle the functional role of some of the observed
changes, our results indicate that a distorted DNA methylation
landscape is a hallmark of human neurodegeneration.
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Figure 4. Pyrosequencing validation of candidates genes with a shared CpG methylation shift in all neurodegenerative diseases. The box-plots
show the distribution of CpG methylation for each gene in control gray matter and the four neurodegenerative disorders. The central solid
line represents the median; the limits of the box indicate the upper and lower quartiles. The whiskers represent the minimum and maximum
values, excluding outliers (o1.5 × the interquartile range). *Po0.05; **Po0.01; and ***Po0.001 in Fisher’s exact test.
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